ANACOR PHARMACEUTICALS INC Inactive Instrument
Company Anacor Pharmaceuticals Inc
Equities
US0324201013
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2016 | Anacor Pharmaceuticals : received rival bid before Pfizer deal - filing | RE |
| 2016 | Anacor Pharmaceuticals : Pfizer to buy Anacor in $5.2 billion deal for access to eczema gel | RE |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
| Chief Tech/Sci/R&D Officer | 77 | 04-01-31 | |
| Director/Board Member | - | 16-06-23 | |
| General Counsel | 75 | 09-12-31 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Douglas Giordano
CEO | Chief Executive Officer | 61 | 16-06-23 |
Bryan Supran
BRD | Director/Board Member | - | 16-06-23 |
| Director/Board Member | - | 16-06-23 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 45,366,886 | 42,957,738 ( 94.69 %) | 0 | 94.69 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| -0.10% | 42.07B | |
| +48.26% | 42.16B | |
| +4.43% | 39.77B | |
| -11.36% | 26.68B | |
| +5.67% | 24.68B | |
| -22.84% | 18.68B | |
| -0.20% | 12.11B | |
| +26.30% | 11.99B | |
| +6.91% | 11.06B |
- Stock Market
- Equities
- Stock
- Company Anacor Pharmaceuticals Inc
